1 Multiple sclerosis disease-modifying therapies and COVID-19 vaccines: A

2 practical review and meta-analysis

Masoud Etemadifar^a; Hosein Nouri^{a,b}; Maristella Pitzalis^c; Maria Laura Idda^c; Mehri Salari^d; Mahshid
 Baratian^e; Sepide Mahdavi^e; Amir Parsa Abhari^{a,b}; Nahad Sedaghat^{a,b}*.

- a) Isfahan Research Committee of Multiple Sclerosis (IRCOMS), Isfahan Multiple Sclerosis Center,
 Isfahan Multiple Sclerosis Society, Isfahan, Iran.
- b) Network of Immunity in Infection, Malignancy, and Autoimmunity (NIIMA), Universal Scientific
 Education and Research Network (USERN), Isfahan, Iran.
- 9 c) Institute for Genetic and Biomedical Research (IRGB) of National Research Council (CNR),
 10 Cagliari, Italy.
- d) Functional Neurosurgery Research Center, Shohada Tajrish Comprehensive Neurosurgical
 Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- e) Clinical Research Development Center, Islamic Azad University of Najafabad, Isfahan, Iran.
- 14 *Corresponding Author:
- 15 Nahad Sedaghat
- 16 Isfahan Research Committee of Multiple Sclerosis (IRCOMS), Isfahan Multiple Sclerosis Center, Isfahan
- 17 Multiple Sclerosis Society, Isfahan, Iran.
- 18 Email: nahad.sedahat@gmail.com
- 19 ORCID: 0000-0002-2796-6791
- 20 Manuscript Details:
- 21 Abstract word count: 382
- 22 Main text word count: 3414
- 23 Number of tables: 2
- 24 Number of figures: 2
- 25 Number of references: 85
- 26 Number of supplementary files: 2

27 Abstract

Importance: An evidence-based appraisal of the COVID-19 vaccination policies among people with multiple sclerosis (pwMS) with respect to disease-modifying therapies (DMT) is important for our understandings and their further management.

Objective: To synthesize the available evidence concerning the effect of DMTs on COVID-19 vaccination
 immunogenicity and effectiveness.

Data Sources: We searched MEDLINE, Scopus, Web of Science, MedRxiv, and Google Scholar from
 January 2021 until January 2022.

Study Selection: The exclusion criteria included: not a primary investigation; retracted/withdrawn; no eligible participants – people with no history/evidence of previous COVID-19 and corticosteroid administration within two months of vaccination; no eligible exposures – all nine DMT classes; and no eligible comparators – DMT-unexposed at the time of vaccination.

39 Data Extraction and Synthesis: Entries were assessed independently by two reviewers for eligibility and 40 quality. Dichotomized data was extracted by two reviewers in accordance with Cochrane guidelines, and 41 were pooled using either Peto fixed-effects or Inverse-variance random-effects methods.

42 **Main Outcomes and Measures:** Main outcomes were i) B-cell response, measured by seroconversion 43 odds ratio (OR); ii) T-cell response, measured by interferon-gamma release response OR, and 44 CD4+/CD8+ activation-induced marker+ OR. Further outcomes including immunity waning speed and 45 breakthrough COVID-19 incidence/severity were synthesized narratively.

Results: Data from 28 studies (5,025 pwMS and 1,635 healthy participants) after COVID-19 vaccination 46 47 suggests mildly-lower B-cell responses in teriflunomide- and alemtuzumab-treated, extensively-lower B-48 cell responses in sphingosine-1-phosphate receptor modulator (S1PRM)- and anti-CD20 (aCD20)-treated, 49 and lower T-cell responses in interferon-, S1PRM-, alemtuzumab- and cladribine-treated pwMS. Every 50 ten-week increase in aCD20-to-vaccine period is associated with a 1.94-time (95%CI: 1.57, 2.41, 51 P<0.00001) increase in odds of seroconversion. B-cell-depleting therapies seem to accelerate post-52 vaccination humoral waning, and booster immunogenicity is predictable with the same factors affecting 53 the priming vaccination. Furthermore, comparatively-increased breakthrough COVID-19 incidence and 54 severity is being observed only among S1PRM- and anti-CD20-treated pwMS - i.e., among the pwMS 55 with extensively-blunted B-cell response, despite adequate T-cell responses in the aCD20-treated. To 56 date, pwMS on only-T-cell-blunting DMTs have not shown increased susceptibility to breakthrough 57 COVID-19.

- 58 Conclusion and Relevance: The implemented vaccination strategy to date has been effective for pwMS
- on all DMTs other than S1PRM and aCD20. As B-cell immunity seems to be a more important predictor of
- 60 vaccine effectiveness than T-cell immunity, optimization of humoral immunogenicity and ensuring its
- 61 durability among pwMS on DMTs are the necessities of an effective COVID-19 vaccination policy.
- 62 **Key Words:** multiple sclerosis; disease-modifying therapies; COVID-19; vaccination; meta-analysis.

63 **1. Introduction**

From the beginning of the coronavirus disease 2019 (COVID-19), global mass vaccination has been the most prominent effort of humanity to end the reign of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Ever since, many vaccines have been developed, all with reasonable safety and efficacy profiles (more information available at: https://covid19.trackvaccines.org/agency/who).

As the effectiveness of COVID-19 vaccination was thought to be altered in people with multiple sclerosis (pwMS) who receive immunomodulatory disease-modifying therapies (DMTs), expert panels issued adjusted vaccination guidelines for pwMS based on previous knowledge of the DMTs' mechanisms of action and preliminary real-world evidence ¹⁻⁴. These guidelines mostly concerned people on sphingosine 1-phosphate receptor modulators (S1PRM), anti-CD20 therapies (aCD20), and other B-cell depleting therapies (BCDT), as they were thought to blunt COVID-19 vaccines' immunogenicity.

Furthermore, administration of booster – in most cases, third – doses of COVID-19 vaccines was recommended after observation of waning humoral immunity ⁵ and clinical effectiveness ⁶⁻⁸. It was stressed after showing to be effective against the vaccine-escape ⁹ Omicron variant of the SARS-CoV-2 ¹⁰⁻¹² – regardless of the priming regimen ^{13,14}. Among the pwMS, homologous booster doses were tested as a strategy to immunize the ones who did not seroconvert following their priming regimen.

Now, several months after the mass vaccination of pwMS around the globe, the available real-world evidence seems adequate for a practical appraisal of the COVID-19 vaccination policies among pwMS with respect to their DMT. Hence, in this systematic review and meta-analysis study, we aimed to gather and synthesize the available evidence and highlight the gaps in the literature, providing a direction guide for future research, facilitating further policy makings, and enabling evidence-based management of pwMS.

We hereby reported and discussed the results of our study (PROSPERO id: CRD42021278107) in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (available from: <u>http://www.prisma-statement.org</u>). The detailed methods of our study could be accessed from the online Supplementary Material.

89 **2. Results and Discussion**

Overall, 28 studies including 5,025 pwMS and 1,635 healthy controls were synthesized (*Fig. 1, Table 1*).
 One study ¹⁵ was excluded despite containing eligible participants because their data could not be
 extracted. The studies differed in outcome measurement methods, settings, number of participants, and
 the administered vaccines. The assessed vaccines used either mRNA (BNT162b2, mRNA-1273),
 adenoviral vector (AV) (Ad26.COV2.S, ChAdOx1), or inactivated (CoronaVac, BBIBP-CorV) platforms.

95 Other prominent points of heterogeneity were the used assays, the number/types of assessed DMTs, the 96 usage of different comparators, e.g., healthy participants, pwMS on no DMT etc., and the timepoints of 97 obtaining samples from participants.

98 [Fig. 1] [Table 1]

The results of individual studies, heterogeneity tests, forest and funnel plots, and the detailed rationale
behind each quality assessment – based on NIH tools – is accessible from the online Supplementary
Material. The pooled measures are summarized in both *Table 2 and Figure 2*, along with their certainty
based on GRADE.

103 [Fig. 2] [Table 2]

104 **2.1.** Effect of DMTs on COVID-19 vaccines' immunogenicity

105 2.1.1. Interferons (IFN)

106 Moderate-certainty evidence does not suggest decreased odds of post-vaccination seroconversion in the pwMS on IFNs compared to people unexposed (UX) to DMTs (OR [95%CI]: 0.84 [0.38, 1.83], P=0.66) 107 (Supplementary Figure 1). No seronegative pwMS on IFN were present in four studies ¹⁶⁻¹⁹. Quantitative 108 109 analysis in studies also did not suggest lower concentrations of antibodies among these pwMS postvaccination. In one study, significantly higher concentrations of anti-Spike (S) receptor binding domain 110 (RBD) IgG were detected among pwMS on IFNs, compared to healthy controls¹⁹. Although the authors 111 suggested that IFN-beta 1a therapy may promote the post-vaccination antibody responses in pwMS, this 112 113 finding was not observed in other studies.

114 Very-low-certainty evidence from one study ²⁰ showed lower extents of interferon-gamma release 115 response to the S antigen in samples from pwMS on IFNs, suggesting blunted T-cell response among 116 these people compared to healthy controls (OR [95%CI]: 0.02 [0.00, 0.28], P<0.01). Both CD4+ and 117 CD8+ T-cell responses were reduced in samples of pwMS on IFN compared to UX people, according to 118 flow cytometric analysis in Tortorella et al. study ²⁰.

119 2.1.2. Glatiramer Acetate (GA)

Moderate-certainty evidence did not suggest decreased odds of post-vaccination seroconversion in the pwMS on GA compared to the UX people (OR [95%CI]: 0.87 [0.31, 2.42], P=0.79) (Supplementary Figure 2). Post-vaccination seronegative pwMS on GA were only present in two studies ^{21,22} – all being among the ones receiving inactivated vaccination. Quantitative analysis in suggested no difference in postvaccination antibody concentrations between GA-treated pwMS and the UX people in any study.

One study with limited sample size utilizing AIM assays ²³ (very low-certainty evidence), suggested
 decreased odds of positive response neither in CD4+ (OR not measurable) nor CD8+ (OR [95%CI]: 0.62
 [0.04, 9.00], P=0.72) T-cells. Furthermore, it is worth mentioning that adequate interferon-gamma release

responses were present after SARS-CoV-2 *infection* in these people ²⁴, suggesting favorable T-cell responses.

130 2.1.3. Dimethyl Fumarate (DMF)

Moderate-certainty evidence did not suggest any decrease in odds of post-vaccination seroconversion among pwMS on DMF compared to UX people (OR [95%CI]: 1.98 [0.96, 4.09], P=0.07) (Supplementary Figure 3). Seven studies ^{16,18,19,22,23,25,26} did not contain any seronegative pwMS on DMF following mRNA or inactivated vaccination; Quantitative analysis suggested no difference in post-vaccination antibody concentrations compared to UX people.

Similar to GA-treated pwMS, evidence on T-cell responses among these pwMS was limited to one study
with a limited sample size ²³ (very-low-certainty evidence), which by utilizing AIM assays, suggested no
decrease in odds of positive responses in subsets of CD4+ (OR not measurable) and CD8+ (OR [95%CI]:
3.78 [0.18, 78.38], P=0.39) T-cells. Similarly, interferon-gamma release responses were sufficient in
DMF-treated pwMS after SARS-CoV-2 *infection*, suggesting adequate T-cell response ²⁴.

141 2.1.4. Teriflunomide (TERI)

142 Inadequate number of studies with considerable heterogeneity (very-low-certainty evidence) suggest 143 decreased odds of post-vaccination seroconversion in pwMS on TERI compared to UX people (OR [95%CI]: 0.38 [0.16, 0.90], P=0.03) (Supplementary Figure 4). Due to low number of mRNA vaccine 144 145 studies with measurable relative effect and therefore, the uncertainty of their pooled measures, the difference between the inactivated and mRNA measures did not reach statistical significance (Chi²=2.91, 146 P=0.09). Nevertheless, considering that none of the TERI-treated pwMS in any of the studies ^{16,18,22,25-28} 147 148 remained seronegative after mRNA vaccination, the suggested blunt caused by TERI may not be generalizable to the mRNA-vaccinated pwMS. Furthermore, lower antibody concentrations compared to 149 150 UX people were observed in pwMS on TERI homogenously in all studies regardless of the used vaccine, but reached statistical significance only in one ²⁸. TERI's mechanism of action – which involves inhibition 151 152 of rapidly-dividing cells, including activated B-cells – may explain this observation.

Furthermore, no evidence was found regarding the T-cell responses in these pwMS following vaccination;
Assessing the vaccine-induced T-cell responses in TERI-treated pwMS is therefore encouraged.

155 2.1.5. Sphingosine-1-phosphate receptor modulators (S1PRM)

High-certainty evidence confirms significantly lower odds of post-vaccination seroconversion in pwMS on
S1PRM compared with UX people (OR [95%CI]: 0.04 [0.03, 0.06], P<0.00001) (Supplementary Figure 5).
All included studies ^{16,17,19-22,25-31} found significantly lower concentrations of antibodies following
vaccination in these pwMS compared to UX people. Studies with heterogenous effect measures
(moderate-certainty evidence) indicate that with the current vaccination strategy, pwMS on S1PRM are 25
times (95%CI: 16.66, 33.33) less likely to show anti-S1, and 8.33 times (95%CI: 3.70, 20) less likely to
show anti-S seroconversion following COVID-19 vaccination (Chi²=7.24, P<0.01). Paradoxical to the

healthy population, low-certainty evidence – due to limited count of inactivated vaccine studies – suggests that among the pwMS on S1PRM, odds of anti-S1 seroconversion is higher with inactivated vaccines compared to mRNA and AV vaccines (Chi²=11.97, P<0.001). Although theoretically reasonable ³², headto-head mRNA-AV ²⁹ and mRNA-inactivated ²² immunogenicity comparisons in S1PRM-treated pwMS have suggested the opposite. Hence, the need for more replication of inactivated/mRNA/AV comparisons is clearly sensed for pwMS on S1PRM.

Furthermore, interferon-gamma release assays in two studies 20,26 (low-certainty evidence) suggested decreased odds of positive T-cell response in pwMS on S1PRM (OR [95%CI]: 0.04 [0.02, 0.07], P<0.00001) (Supplementary Figure 6). AIM assay in another study 23 (very-low-certainty evidence) did not suggest decreased odds of CD8+ T-cell response in these pwMS (OR [95%CI]: 0.95 [0.08, 10.71], P=0.97) but suggested decreased odds of CD4+ T-cell responses (OR [95%CI]: 0.01 [0.00, 0.18], P=0.001) compared to UX people.

Additionally, among the pwMS on S1PRM who failed to seroconvert following priming vaccination, one
 study showed that administration of booster doses increased anti-S1 antibody concentrations, but
 promoted seroconversion only in 2/29 (7%) ³³.

178 The trafficking inhibition of lymphocytes, their restriction to lymphatics, and hence, the peripheral 179 lymphopenia seen in pwMS on S1PRM explains the lower T-cell reactivity observed in peripheral blood samples – not to mention S1PRM's documented inhibitive effect on T-cell activation ³⁴. The former reason 180 may also explain the blunted humoral responses, as the one-way flow of lymph from peripheral to central 181 182 areas restricts trafficking of lymphocytes to peripheral areas, inhibiting proper exposure of lymph-trapped 183 lymphocytes to immunizing materials of the vaccines which are administered peripherally/locally. As systemic SARS-CoV-2 infection mounts adequate immunization among pwMS on S1PRM ^{32,35}, it can be 184 hypothesized that immunogenicity in these people is subject to wider (e.g., systemic instead of 185 local/peripheral) exposure to immunogens. When the lymphocytes' ability to reach the immunogens is 186 187 inhibited, the immunogens should reach the lymphocytes themselves or immunization will not develop.

188 2.1.6. Natalizumab (NTZ)

189 Compared to UX people, low-certainty evidence did not confirm lower odds of anti-S1 seroconversion among pwMS on NTZ following vaccination (OR [95%CI]: 0.53 [0.24, 1.18]) (Supplementary Figure 7). All 190 191 pwMS on NTZ in seven studies - including the only two studies using anti-S assays with extractable data ^{23,36} – seroconverted following vaccination ^{16,17,23,25,26,28,36}. Although relative effect was measurable in only 192 two of them which contained seronegative UX people ^{26,28}. Unlike all the other studies, pwMS on NTZ in 193 one study ²⁸ showed significantly lower post-vaccination antibodies compared to UX people. Interferon-194 gamma release ¹⁷ and AIM ²³ assays (very low-certainty evidence) did not suggest blunted post-195 196 vaccination T-cell responses in pwMS on NTZ compared to UX people.

197 NTZ, an anti-α4-integrin monoclonal antibody, implements its effect by inhibiting lymphocyte 198 extravasation; however, unlike S1PRM, its lymphocyte trafficking inhibition does not trap the lymphocytes 199 in the lymphatic system – i.e., it does not cause peripheral lymphopenia. Although their trafficking abilities 200 are inhibited, the preserved presence of lymphocytes in blood flow – which, unlike the lymph flow, can be 201 from central to peripheral areas as well – may be the reason NTZ does not blunt vaccination-induced 202 immunization as much as S1PRM.

203 **2.1.7.** Cladribine (CLAD)

204 Pooled low-certainty evidence (Supplementary Figure 8) confirms no difference in odds of anti-S1 205 seroconversion among pwMS on CLAD compared to UX people (OR [95%CI]: 0.41 [0.15, 1.11], P=0.08). No evidence was found regarding anti-S seroconversion. In five studies ^{16,19,20,22,25}, all CLAD-treated 206 207 pwMS seroconverted following vaccination similar to the UX people, preventing relative effect 208 measurement. Quantitative analysis in no studies suggested lower concentrations of post-vaccination antibodies among them. Assessment of vaccination-induced T-cell response was limited to one study ²⁰ 209 210 (very-low-certainty evidence); it showed lower odds of positive S-induced interferon-gamma release 211 responses in samples from pwMS on CLAD compared to UX people (OR [95%CI]: 0.01 [0.00, 0.04], 212 P<0.00001).

213 Compared to its effect on the T-cell lineage, CLAD's effect on the B-cells is more extensive but less durable ³⁷⁻⁴⁰. As interpreted, this has been translated into observation of proper humoral despite blunted 214 215 cellular immunization following COVID-19 vaccination among pwMS on CLAD. Furthermore, the time since the last CLAD dose theoretically affects humoral responses; This was suggested especially by 216 Achiron et al. study ²⁶ but did not reach statistical significance, and was not confirmed by other studies 217 ^{25,28,41}; It seems the implemented guidelines ¹⁻⁴ have suggested an adequate amount of post-CLAD 218 vaccination delay to prevent blunted humoral responses, and therefore, made the probable effect 219 unmeasurable. Additionally, although CLAD depletes the memory B-cells ⁴², a preliminary study 220 221 suggested its subsequent doses will not alter pre-existing humoral memory 43; Still, there is limited 222 evidence that the longevity of COVID-19 vaccine-induced humoral responses is lower in pwMS on CLAD ²⁶. Replicative studies measuring the immunity waning speed in these pwMS after COVID-19 vaccination 223 224 are, therefore, required to determine whether they require personalized booster schedules.

225 2.1.8. Alemtuzumab (ALEM)

Pooled very-low-certainty evidence (Supplementary Figure 9) suggests lower odds of anti-S1 seroconversion among pwMS on ALEM compared to UX people (OR [95%CI]: 0.32 [0.10, 0.96], P=0.04). One study assessed anti-S seroconversion, but its data could not be extracted ³⁰. PwMS on ALEM in three studies ^{16,25,28} showed 100% seroconversion rates similar to the UX people in two of them ^{16,25}, and none of the studies suggested lower concentrations of post-vaccination antibodies among them – not even the study that indicated lower odds of seroconversion ²⁶. Vaccination-induced T-cell responses were

not assessed in any of the included studies, still, ALEM's durable effect of T-cell lineage ⁴⁴ suggests that
 they are blunted .

ALEM, an anti-CD52 monoclonal antibody, is known to significantly deplete B- and T-cells shortly after administration. ALEM's short-term effect on B- and T-cell dynamics is relatively similar to CLAD ^{40,44}. Hence, although the time from the last ALEM infusion affects seroconversion ²⁶, this effect is currently not measurable as the implemented guidelines ¹⁻⁴ seem to have suggested an adequate amount of delay. Similar to other BCDT, further studies measuring comparative immunity waning speeds in pwMS on ALEM are needed to determine whether they require more frequent boosters.

240 2.1.9. Anti-CD20 therapies (aCD20)

High-certainty evidence confirms lower odds of seroconversion following COVID-19 vaccination among 241 242 pwMS on aCD20 compared to UX people (OR [95%CI]: 0.05 [0.04, 0.06], P<0.00001) (Supplementary 243 Figure 10). Studies with heterogenous effect measures (moderate-certainty evidence) indicate that with 244 the currently-implemented strategies, pwMS on aCD20 are 20 times (95%CI: 16.66, 25) less likely to 245 seroconvert for anti-S1, and 12.5 times (95%CI: 7.69, 20) less likely to seroconvert for anti-S antibodies (Chi²=2.76, P=0.10) following COVID-19 vaccination. Quantitative analyses in all included studies 246 247 confirmed this observation. Furthermore, evidence indicates with high certainty that every 10-week delay 248 in subsequent aCD20 infusion is associated with a 1.94-time (95%CI: 1.57, 2.41, P<0.00001) increase in 249 seroconversion odds of pwMS on aCD20 (Supplementary Figure n).

Regarding the T-cell responses, compared to UX people, moderate-certainty evidence does not suggest
different odds of positive post-vaccination T-cell interferon-gamma release responses (OR [95%CI]: 1.12
[0.62, 2.05], P=0.70) (Supplementary Figure 12), CD8+ (OR [95%CI]: 2.54 [0.89, 7.27], P=0.08)
(Supplementary Figure 13), and CD4+ (OR [95%CI]: 1.13 [0.17, 7.61], P=0.90) T-cell AIM responses.
Quantitative analyses in most studies ^{17,20,23,29,45-48} were in line with the dichotomized evidence. Multiplex
polymerase chain reaction assay in one study ⁴⁹ indicated positive adaptive T-cell responses among 100%
of seronegative pwMS on aCD20 following vaccination.

Furthermore, the preliminary evidence indicates significant decline in seropositivity rates of pwMS on aCD20 six months after their second dose ^{50,51}. Homologous mRNA boosters in pwMS on aCD20 promoted T-cell responses ⁵², while humoral responses were still heavily dependent on the serostatus following the priming regimen, and B-cell dynamics at the time of booster administration ^{33,51-53}; In other words, the booster doses did not promote humoral immunization in pwMS on aCD20 who did not seroconvert following priming vaccination, unless their B-cells were reconstituted. Studies among people on aCD20 with diseases other than MS ^{54,55} support the same conclusion.

Similar to pwMS on other DMTs, the COVID-19 vaccines' immunogenicity among pwMS on aCD20 could be considered a translation of the previously-determined B- and T-cell dynamics in them ^{40,56}, based on which the current guidelines recommended a 12-to-36-week window between aCD20 infusion and

COVID-19 vaccination ¹⁻⁴. However, the presented evidence suggests that the mentioned interval, 267 although increases the odds, will not be adequate to reverse the humoral blunts in pwMS on aCD20 (Fig. 268 3). The alterations in the dynamics of B-cells in people receiving aCD20 last for years according to the 269 unpublished results from the NCT00676715 phase-II extension trial ⁵⁷, suggesting durable, long-lasting 270 benefits of aCD20 without subsequent dosing ⁵⁸. However, this durable effect of aCD20 has shown to be 271 able to alter vaccine immunogenicity for as long as three years, as observed in people with hematological 272 273 malignancies ⁵⁹. Hence, prior B-cell profiling and post-vaccination serological screening may be the 274 necessities of an effective personalized vaccination strategy in pwMS who received aCD20 at any time 275 point within three years.

276 [Fig. 3]

277 2.2. Vaccine types

278 Based on phase-III data, the efficacy profiles of different available COVID-19 vaccine types (i.e., mRNA, 279 AV, inactivated, and protein-based) seems to correlate to their anti-S/S1 humoral immunogenicity - both in healthy people ^{60,61} and pwMS ⁶². Head-to-head comparisons of the available COVID-19 vaccines' 280 281 humoral immunogenicity among pwMS reveals the superiority of mRNA-1237 over BNT162b2 (both mRNA-based) ^{20,25,63} – probably due to higher concentrations of active material, BNT162b2 and mRNA-282 1237 (mRNA) over ChAdOx1 and Ad26.COV2 (AV) ^{17,23,29,49} and BNT162b2 (mRNA) over CoronaVac 283 (inactivated)²² – although humoral immunization did not differ significantly in pwMS on aCD20 receiving 284 BNT162b2 and CoronaVac in Ozakbas et al. ²² study. The choice of a specific vaccine type among pwMS 285 is encouraged and should be based on an individualized risk/benefit assessment with careful 286 consideration of their COVID-19 risk factor profile ^{64,65}, their DMT, and the availability/cost-effectiveness 287 of the vaccine 66,67. 288

289 2.3. Moving into the clinic

While the serum anti-S/S1 assays are deemed predictive of its neutralizing activity ^{68,69}, and the serum 290 neutralizing activity predictive of the clinical protection against symptomatic SARS-CoV-2 infection ⁷⁰, 291 292 pwMS with adequate humoral responses - mostly on DMTs other than aCD20 and S1PRM - would 293 theoretically show adequate protection against SARS-CoV-2. However, in the absence of humoral immunization, it is doubted if the T-cells could provide adequate clinical protection among pwMS on 294 295 aCD20 and S1PRM. The current real-world evidence confirms the predictive effect of seroconversion on post-vaccination COVID-19 incidence and severity ⁶², and indicates rising comparative incidence and 296 severity of COVID-19 among pwMS on S1PRM and aCD20 following vaccination of pwMS^{62,71-73}. The 297 298 less-extensive humoral blunts in pwMS on TERI – and possibly ALEM – do not seem to have had any significant effect on vaccine effectiveness. Regarding the protective effect of T-cell responses, currently, 299 the only clue lies within the Etemadifar et al.⁷² study – although not confirmed by a larger study ⁷³; it 300 301 showed that among the vaccinated pwMS, the ones on aCD20 experienced lower incidence and severity

of COVID-19 in comparison with those on fingolimod. The former are known to be prone to worse COVID-19 outcomes ⁶⁴ but show robust post-vaccination T-cell responses, while the latter do not develop proper T-cell immunization following vaccination. Still, the practical protective effect of T-cell responses in the absence of antibodies could neither be confirmed nor measured until further real-world evidence becomes available.

307 **3. Conclusion**

308 The present analysis highlight and corroborate the relevance for an optimal treatment strategy in pwMS 309 before COVID-19 vaccination. It was demonstrated that the current vaccination strategy has failed to 310 promote adequate humoral immunity in aCD20- and S1PRM-treated pwMS, which is being translated into 311 low clinical effectiveness of COVID-19 vaccines among them - despite adequate T-cell responses in the ones on aCD20. Their susceptibility to worse COVID-19 outcomes, and the dependency of COVID-19 312 313 vaccines' humoral immunogenicity to the B-cell dynamics at the time of administration - and therefore, 314 the timing of aCD20 infusion – stress the importance of personalizing vaccination strategies for pwMS on 315 aCD20 with respect to their B-cell profiles and aCD20 infusion timings. Theoretically and based on limited 316 evidence, mode of action and administration method may be important factors to consider also when 317 vaccinating S1PR modulator-treated pwMS, while more evidence is needed to support this claim. Milder 318 humoral and considerable T-cell response blunts - also depending on dosage timings, and higher 319 immunity waning speeds may be present in pwMS on CLAD and ALEM, which subject to confirmation by 320 further evidence, stresses the importance of earlier booster administrations among them. TERI may also 321 cause a humoral immunogenicity blunt, however, being less extensive and clinically-irrelevant based on 322 current evidence; PwMS on TERI may not require countering policies other than being provided with 323 reliable information about the importance of booster doses. Evidence to date does not indicate any significant effect of IFN, GA, DMF, and NTZ on COVID-19 vaccines' immunogenicity and effectiveness. 324

Additionally, as heterologous boosters among healthy people showed to be more immunogenic and effective ⁷⁴, further replication among pwMS with heterologous regimens is encouraged, especially among the ones primed with inactivated vaccines – as samples from inactivated-vaccinated people show less neutralizing activity against the Omicron variant ⁷⁵, and the heterologous boosters with superiority of mRNA ^{13,14,76-78} over AV ⁷⁹ have shown to be more immunogenic than homologous boosters in healthy people receiving inactivated priming regimens.

331 4. Acknowledgements

332 We would like to thank Prof. Mohammad Reza Maracy for his valuable methodological consultations.

5. Conflict of Interest and Funding

The authors declare no conflict of interest. This study did not receive any funding.

335 **6. References**

1. Timing MS Medications with COVID-19 Vaccines. National MS Society. 336 Accessed 19 November 2021. https://www.nationalmssociety.org/coronavirus-covid-19-337 information/multiple-sclerosis-and-coronavirus/covid-19-vaccine-guidance/Timing-MS-338 Medications-with-COVID-19-Vaccines 339 Yamout BI, Zakaria M, Inshasi J, et al. MENACTRIMS practice guideline for 340 2. COVID-19 vaccination in patients with multiple sclerosis. *Multiple Sclerosis and Related* 341 342 Disorders, 2021:56:103225. 343 3. MS, DMTs and COVID-19 vaccines consensus statement. Multiple Sclerosis 2022. https://www.mssocietv.org.uk/what-we-Accessed Januarv. 344 Society. 13 do/news/ms-society-medical-advisers-release-consensus-statement-covid-19-vaccines 345 Wolf A, Alvarez E. COVID-19 Vaccination in Patients With Multiple Sclerosis on 346 4. Disease-Modifying Therapy. Neurology: Clinical Practice. 2021; 347 Levin EG, Lustig Y, Cohen C, et al. Waning immune humoral response to 5. 348 349 BNT162b2 Covid-19 vaccine over 6 months. New England Journal of Medicine. 2021:385(24):e84. 350 Goldberg Y, Mandel M, Bar-On YM, et al. Waning immunity after the BNT162b2 351 6. vaccine in Israel. New England Journal of Medicine. 2021;385(24):e85. 352 353 7. Rosenberg ES, Dorabawila V, Easton D, et al. Covid-19 Vaccine Effectiveness in New York State. Ν Engl Med. Jan 13 2022;386(2):116-127. 354 J 355 doi:10.1056/NEJMoa2116063 Lin DY, Gu Y, Wheeler B, et al. Effectiveness of Covid-19 Vaccines over a 9-356 8. Month Period in North Carolina. Ν Engl J Med. Jan 12 357 2022;doi:10.1056/NEJMoa2117128 358 Edara VV, Manning KE, Ellis M, et al. mRNA-1273 and BNT162b2 mRNA 359 9. vaccines have reduced neutralizing activity against the SARS-CoV-2 Omicron variant. 360 361 bioRxiv. Dec 22 2021;doi:10.1101/2021.12.20.473557 Accorsi EK, Britton A, Fleming-Dutra KE, et al. Association Between 3 Doses of 362 10. mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 363 Omicron and Delta Variants. Jama. Jan 21 2022;doi:10.1001/jama.2022.0470 364 11. Gruell H, Vanshylla K, Tober-Lau P, et al. mRNA booster immunization elicits 365 potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. Nat Med. 366 Jan 19 2022:1-4. doi:10.1038/s41591-021-01676-0 367 Garcia-Beltran WF, St Denis KJ, Hoelzemer A, et al. mRNA-based COVID-19 368 12. vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. 369 Cell. Jan 6 2022;doi:10.1016/j.cell.2021.12.033 370 Pérez-Then E, Lucas C, Monteiro VS, et al. Neutralizing antibodies against the 371 13. SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus 372 373 BNT162b2 booster vaccination. Nat Med. Jan 20 2022;doi:10.1038/s41591-022-01705-374 6 Cheng SMS, Mok CKP, Leung YWY, et al. Neutralizing antibodies against the 375 14. SARS-CoV-2 Omicron variant following homologous and heterologous CoronaVac or 376 BNT162b2 vaccination. Nat Med. Jan 20 2022;doi:10.1038/s41591-022-01704-7 377

15. Bigaut K, Kremer L, Fleury M, Lanotte L, Collongues N, de Seze J. Impact of disease-modifying treatments on humoral response after COVID-19 vaccination: a mirror of the response after SARS-CoV-2 infection. *Revue Neurologique*. 2021;

16. Capone F, Lucchini M, Ferraro E, et al. Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different diseasemodifying therapies. *Neurotherapeutics*. 2021:1-9.

17. Gadani SP, Reyes-Mantilla M, Jank L, et al. Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy. *EBioMedicine*. 2021;73:103636.

- 18. Giossi R, Consonni A, Clerici VT, et al. Anti-Spike IgG in multiple sclerosis
 patients after BNT162b2 vaccine: An exploratory case-control study in Italy. *Multiple Sclerosis and Related Disorders*. 2021:103415.
- Maniscalco GT, Manzo V, Ferrara AL, et al. Interferon Beta-1a treatment
 promotes SARS-CoV-2 mRNA vaccine response in multiple sclerosis subjects. *Multiple sclerosis and related disorders*. 2022;58:103455.
- 393 20. Tortorella C, Aiello A, Gasperini C, et al. Humoral-and T-Cell Specific Immune
 394 Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different
 395 Disease-Modifying Therapies. *Neurology*. 2021;
- 21. Etemadifar M, Sedaghat N, Nouri H, et al. SARS-CoV-2 serology among people with multiple sclerosis on disease-modifying therapies after BBIBP-CorV (Sinopharm) inactivated virus vaccination: Same story, different vaccine. *Multiple Sclerosis and Related Disorders*. 2022;57:103417.
- 22. Ozakbas S, Baba C, Dogan Y, Cevik S, Ozcelik S, Kaya E. Comparison of
 SARS-CoV-2 antibody response after two doses of mRNA and inactivated vaccines in
 multiple sclerosis patients treated with disease-modifying therapies. *Multiple sclerosis* and related disorders. 2022:103486.
- Sabatino Jr JJ, Mittl K, Rowles W, et al. Impact of multiple sclerosis disease modifying therapies on SARS-CoV-2 vaccine-induced antibody and T cell immunity.
 medRxiv. 2021;
- 407 24. Kister I, Patskovsky Y, Curtin R, et al. Cellular and humoral immunity to SARS-408 CoV-2 infection in multiple sclerosis patients on ocrelizumab and other disease-409 modifying therapies: a multi-ethnic observational study. *medRxiv*. 2022;
- Sormani MP, Inglese M, Schiavetti I, et al. Effect of SARS-CoV-2 mRNA
 vaccination in MS patients treated with disease modifying therapies. *EBioMedicine*.
 2021;72:103581.
- 413 26. Achiron A, Mandel M, Dreyer-Alster S, et al. Humoral immune response in 414 multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 415 months cross-sectional study. *Journal of Neuroimmunology*. 2021;361:577746.
- 27. Disanto G, Sacco R, Bernasconi E, et al. Association of disease-modifying
 treatment and anti-CD20 infusion timing with humoral response to 2 SARS-CoV-2
 vaccines in patients with multiple sclerosis. *JAMA neurology*. 2021;78(12):1529-1531.
- 28. Pitzalis M, Idda ML, Lodde V, et al. Effect of different disease-modifying
 therapies on humoral response to BNT162b2 vaccine in Sardinian multiple sclerosis
 patients. *Frontiers in immunology*. 2021:5233.
- 422 29. Tallantyre EC, Vickaryous N, Anderson V, et al. COVID 19 Vaccine Response
 423 in People with Multiple Sclerosis. *Annals of neurology*. 2022;91(1):89-100.

424 30. König M, Lorentzen ÅR, Torgauten HM, et al. Humoral immunity to SARS-CoV-2 425 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab 426 infusion and first experience from sporadic revaccinations. *Journal of Neurology,* 427 *Neurosurgery & Psychiatry*. 2021;

428 31. Türkoğlu R, Baliç N, Kızılay T, et al. 7Fingolimod impairs inactivated vaccine 429 (CoronaVac)-induced antibody response to SARS-CoV-2 spike protein in persons with 430 multiple sclerosis. *Multiple Sclerosis and Related Disorders*. 2022:103524.

32. Rommer PS, Bsteh G, Berger T, Zettl UK. SARS-CoV-2 antibodies in multiple
sclerosis patients depending on the vaccine mode of action? *Multiple Sclerosis Journal*.
2022;28(1):165-167.

- 434 33. König M, Torgauten HM, Øverås MH, et al. Efficacy and safety of a third SARS-435 CoV-2 vaccination in multiple sclerosis vaccine non-responders. *medRxiv*. 436 2021:2021.10.15.21264977. doi:10.1101/2021.10.15.21264977
- 437 34. Baer A, Colon-Moran W, Bhattarai N. Characterization of the effects of 438 immunomodulatory drug fingolimod (FTY720) on human T cell receptor signaling 439 pathways. *Scientific Reports*. 2018/07/19 2018;8(1):10910. doi:10.1038/s41598-018-440 29355-0
- 35. Sormani MP, Schiavetti I, Landi D, et al. SARS-CoV-2 serology after COVID-19
 in multiple sclerosis: An international cohort study. *Multiple Sclerosis Journal*.
 2021:13524585211035318.
- 444 36. Capuano R, Donnarumma G, Bisecco A, et al. Humoral response to SARS-CoV445 2 mRNA vaccine in patients with multiple sclerosis treated with natalizumab.
 446 Therapeutic Advances in Neurological Disorders. 2021;14:17562864211038111.
- 37. Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine
 for relapsing multiple sclerosis. *New England Journal of Medicine*. 2010;362(5):416-426.
 38. Duddy M, Niino M, Adatia F, et al. Distinct effector cytokine profiles of memory
 and naive human B cell subsets and implication in multiple sclerosis. *The Journal of Immunology*. 2007;178(10):6092-6099.
- 452 39. Comi G, Cook S, Giovannoni G, et al. Effect of cladribine tablets on lymphocyte
 453 reduction and repopulation dynamics in patients with relapsing multiple sclerosis.
 454 *Multiple sclerosis and related disorders*. 2019;29:168-174.
- 40. Baker D, MacDougall A, Kang AS, Schmierer K, Giovannoni G, Dobson R. CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis. *Multiple Sclerosis and Related Disorders*. 2022;57:103448.
- 459 41. Grothe C, Steffen F, Bittner S. Humoral immune response and lymphocyte levels
 after complete vaccination against COVID-19 in a cohort of multiple sclerosis patients
 treated with cladribine tablets. *Journal of Central Nervous System Disease*.
 2021;13:11795735211060118.
- 463 42. Baker D, Marta M, Pryce G, Giovannoni G, Schmierer K. Memory B cells are 464 major targets for effective immunotherapy in relapsing multiple sclerosis. *EBioMedicine*. 465 2017;16:41-50.
- 466 43. Moser T, O'Sullivan C, Puttinger C, et al. Pre-Existing Humoral Immunological
- Memory Is Retained in Patients with Multiple Sclerosis Receiving Cladribine Therapy.
 Biomedicines. 2021;9(11):1584.

469 44. Ruck T, Bittner S, Wiendl H, Meuth SG. Alemtuzumab in multiple sclerosis: 470 mechanism of action and beyond. *International journal of molecular sciences*. 471 2015;16(7):16414-16439.

472 45. Apostolidis SA, Kakara M, Painter MM, et al. Cellular and humoral immune 473 responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis 474 on anti-CD20 therapy. *Nature medicine*. 2021;27(11):1990-2001.

- 475 46. Madelon N, Lauper K, Breville G, et al. Robust T cell responses in anti-CD20 476 treated patients following COVID-19 vaccination: a prospective cohort study. *Clinical* 477 *Infectious Diseases*. 2021;
- 478 47. Brill L, Rechtman A, Zveik O, et al. Humoral and T-cell response to SARS-CoV-2
 479 vaccination in patients with multiple sclerosis treated with ocrelizumab. *JAMA neurology*.
 480 2021;78(12):1510-1514.
- 481 48. Pompsch M, Fisenkci N, Horn PA, Kraemer M, Lindemann M. Evidence of 482 extensive cellular immune response after SARS-CoV-2 vaccination in ocrelizumab-483 treated patients with multiple sclerosis. *Neurological Research and Practice*. 484 2021;3(1):1-6.
- 485 49. Katz J, Bouley A, Jungquist R, Douglas E, O'Shea I, Lathi E. Humoral and T-cell 486 responses to SARS-CoV-2 vaccination in multiple sclerosis patients treated with 487 ocrelizumab. *Multiple Sclerosis and Related Disorders*. 2021:103382.
- 488 50. Bajwa HM, Novak F, Nilsson AC, et al. Persistently reduced humoral and cellular 489 immune response following third SARS-CoV-2 mRNA vaccination in anti-CD20-treated 490 multiple sclerosis patients. *medRxiv*. 2022;
- 491 51. Brill L, Raposo C, Rechtman A, et al. SARS-CoV-2 third vaccine immune 492 response in MS patients treated with ocrelizumab. *medRxiv*. 2022;
- 493 52. Madelon N, Heikkilä N, Sabater Royo I, et al. Omicron-specific cytotoxic T-cell
 494 responses are boosted following a third dose of mRNA COVID-19 vaccine in anti-CD20495 treated multiple sclerosis patients. *medRxiv*. 2021:2021.12.20.21268128.
 496 doi:10.1101/2021.12.20.21268128
- 497 53. Achtnichts L, Jakopp B, Oberle M, et al. Humoral Immune Response after the
 498 Third SARS-CoV-2 mRNA Vaccination in CD20 Depleted People with Multiple Sclerosis.
 499 Vaccines. 2021;9(12):1470.
- 500 54. Felten R, Gallais F, Schleiss C, et al. Cellular and humoral immunity after the 501 third dose of SARS-CoV-2 vaccine in patients treated with rituximab. *Lancet Rheumatol.* 502 Jan 2022;4(1):e13-e16. doi:10.1016/s2665-9913(21)00351-9
- 503 55. Bonelli M, Mrak D, Tobudic S, et al. Additional heterologous versus homologous 504 booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody 505 seroconversion after primary mRNA vaccination: a randomised controlled trial. *Ann* 506 *Rheum Dis.* Jan 13 2022;doi:10.1136/annrheumdis-2021-221558
- 507 56. Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple 508 sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. *The Lancet.* 509 2011;378(9805):1779-1787.
- 510 57. Hauser S, Li D, Calabresi P, et al. Week 144 results of a phase II, randomized, 511 multicenter trial assessing the safety and efficacy of ocrelizumab in patients with
- relapsing remitting multiple sclerosis (RRMS)(S31. 004). AAN Enterprises; 2013.

513 58. Baker D, Pryce G, James LK, Marta M, Schmierer K. The ocrelizumab phase II 514 extension trial suggests the potential to improve the risk: Benefit balance in multiple 515 sclerosis. *Multiple Sclerosis and Related Disorders*. 2020;44:102279.

516 59. Funakoshi Y, Yakushijin K, Ohji G, et al. Increase in Antibody Titers Following 517 Sars-Cov-2 Vaccination Remains Limited for More Than 3 Years after Final Dose of 518 Anti-CD20 Antibody. *Blood*. 2021;138:534.

519 60. Fan Y-J, Chan K-H, Hung IF-N. Safety and Efficacy of COVID-19 Vaccines: A 520 Systematic Review and Meta-Analysis of Different Vaccines at Phase 3. *Vaccines*.

- 521 2021;9(9):989.
- 522 61. Cheng H, Peng Z, Luo W, et al. Efficacy and Safety of COVID-19 Vaccines in 523 Phase III Trials: A Meta-Analysis. *Vaccines*. 2021;9(6):582.
- 62. Sormani MP, Schiavetti I, Inglese M, et al. Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies. *medRxiv*. 2021;
- 527 63. Ali A, Dwyer D, Wu Q, et al. Characterization of humoral response to COVID 528 mRNA vaccines in multiple sclerosis patients on disease modifying therapies. *Vaccine*. 529 2021;39(41):6111-6116.
- 530 64. Etemadifar M, Nouri H, Maracy MR, et al. Risk factors of severe COVID-19 in 531 people with multiple sclerosis: A systematic review and meta-analysis. *Revue* 532 *neurologique*. 2021;
- 533 65. Sormani MP, Schiavetti I, Carmisciano L, et al. COVID-19 severity in multiple 534 sclerosis: putting data into context. *Neurology-Neuroimmunology Neuroinflammation*. 535 2022;9(1)
- 536 66. López F, Català M, Prats C, et al. A Cost-Benefit Analysis of COVID-19 537 Vaccination in Catalonia. *Vaccines (Basel)*. Dec 31 538 2021;10(1)doi:10.3390/vaccines10010059
- 539 67. Vaezi A, Meysamie A. COVID-19 Vaccines Cost-Effectiveness Analysis: A 540 Scenario for Iran. *Vaccines (Basel)*. Dec 29 2021;10(1)doi:10.3390/vaccines10010037
- 68. Kohmer N, Westhaus S, Rühl C, Ciesek S, Rabenau HF. Brief clinical evaluation
 of six high-throughput SARS-CoV-2 IgG antibody assays. *Journal of Clinical Virology*.
 2020/08/01/ 2020;129:104480. doi:<u>https://doi.org/10.1016/j.jcv.2020.104480</u>
- 544 69. Müller L, Ostermann PN, Walker A, et al. Sensitivity of anti-SARS-CoV-2 545 serological assays in a high-prevalence setting. *European Journal of Clinical* 546 *Microbiology & Infectious Diseases*. 2021/05/01 2021;40(5):1063-1071. 547 doi:10.1007/s10096-021-04169-7
- 548 70. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly
 549 predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nature*550 *Medicine*. 2021/07/01 2021;27(7):1205-1211. doi:10.1038/s41591-021-01377-8
- 551 71. Garjani A, Patel S, Bharkhada D, et al. Impact of mass vaccination on SARS-552 CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-553 modifying therapies in England. *Multiple Sclerosis and Related Disorders*. 554 2022;57:103458.
- 555 72. Etemadifar M, Abhari AP, Nouri H, Eighani N, Salari M, Sedaghat N. Effect of 556 Disease-Modifying Therapies on Clinical Efficacy of COVID-19 Inactivated Vaccination 557 among People with Multiple Sclerosis. *Available at SSRN 3998537*. 2022;

558 73. Schiavetti I, Cordioli C, Stromillo ML, et al. Breakthrough SARS-CoV-2 infections
559 in MS patients on disease modifying therapies. *medRxiv*. 2022:2022.01.22.22269630.
560 doi:10.1101/2022.01.22.22269630

561 74. Liu X, Shaw RH, Stuart ASV, et al. Safety and immunogenicity of heterologous
562 versus homologous prime-boost schedules with an adenoviral vectored and mRNA
563 COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. *Lancet.*564 Sep 4 2021;398(10303):856-869. doi:10.1016/s0140-6736(21)01694-9

- 565 75. Peiris M, Cheng S, Mok CKP, et al. Neutralizing antibody titres to SARS-CoV-2 566 Omicron variant and wild-type virus in those with past infection or vaccinated or boosted 567 with mRNA BNT162b2 or inactivated CoronaVac vaccines. *Res Sq.* Jan 5 568 2022;doi:10.21203/rs.3.rs-1207071/v1
- 569 76. Kanokudom S, Assawakosri S, Suntronwong N, et al. Safety and Immunogenicity 570 of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines 571 in Fully Immunized Healthy Adults with Inactivated Vaccine. *Vaccines*. 2022;10(1):86.
- 572 77. Wang X, Zhao X, Song J, et al. Homologous or Heterologous Booster of
 573 Inactivated Vaccine Reduces SARS-CoV-2 Omicron Variant Escape from Neutralizing
 574 Antibodies. *Emerg Microbes Infect.* Jan 15 2022:1-18.
 575 doi:10.1080/22221751.2022.2030200
- 576 78. Zhang R, Liu D, Leung KY, et al. Immunogenicity of a Heterologous Prime-Boost
 577 COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with
 578 Homologous Vaccination Strategy against SARS-CoV-2 Variants. *Vaccines (Basel)*. Jan
 579 3 2022;10(1)doi:10.3390/vaccines10010072
- 580 79. Wanlapakorn N, Suntronwong N, Phowatthanasathian H, et al. Safety and 581 immunogenicity of heterologous and homologous inactivated and adenoviral-vectored 582 COVID-19 vaccines in healthy adults. *medRxiv*. 2021:2021.11.04.21265908. 583 doi:10.1101/2021.11.04.21265908
- 80. Achiron A, Dolev M, Menascu S, et al. COVID-19 vaccination in patients with
 multiple sclerosis: what we have learnt by February 2021. *Multiple Sclerosis Journal*.
 2021:135245852110034.
- 587 81. Achiron A, Mandel M, Dreyer-Alster S, et al. Humoral immune response to 588 COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy 589 disease-modifying therapies. *Therapeutic advances in neurological disorders*. 590 2021;14:17562864211012835.
- 591 82. Gallo A, Capuano R, Donnarumma G, et al. Preliminary evidence of blunted 592 humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated 593 with ocrelizumab. *Neurological Sciences*. 2021;42(9):3523-3526.
- 83. van Kempen Z, Wieske L, Stalman E, et al. Longitudinal humoral response after
 SARS-CoV-2 vaccination in ocrelizumab treated MS patients: To wait and repopulate? *Multiple Sclerosis and Related Disorders*. 2022;57:103416.
- 597 84. Guerrieri S, Lazzarin S, Zanetta C, Nozzolillo A, Filippi M, Moiola L. Serological 598 response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with 599 fingolimod or ocrelizumab: an initial real-life experience. *J Neurol*. 2021;1:1-5.
- 600 85. Novak F, Nilsson AC, Nielsen C, et al. Humoral immune response following 601 SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis.
- Multiple Sclerosis and Related Disorders. 2021;56:103251.
- 603

604 **Tables**

605 Table 1; Characteristics of included studies.

| Study (Location) | Sample size (pwMS, HC) | Vaccine (platform) | B-cell assay (method, manufacturer) | T-cell assay (method, manufacturer) | Study quality* |
|-----------------------------------------------|---------------------------|------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------|-------------------|
| Achiron et al. (Israel) 26,80,81 | 503 (414, 89) | BNT162b2 (mRNA) | Serum anti-S1 IgG (ELISA, EUROIMMUN) PBMC S-induced IgG-secreting B-cells (FluoroSpot, Mabtech) | PBMC S-induced IFN-g-, IL-2- positive T-cells (FluoroSpot, Mabtech) | Good |
| Ali et al. (USA) ⁶³ | 53 (46**, 7) | BNT162b2 (mRNA) mRNA-1273 (mRNA) | Serum Anti-RBD IgG (CLIA, Siemens) | NA | Fair |
| Apostolidis et al. (USA) 45 | 30 (20, 10) | BNT162b2 (mRNA) mRNA-1273 (mRNA) | Serum anti-S IgG (ELISA, NA) Serum anti-RBD IgG (ELISA, NA) PBMC S-induced IgG-secreting B-cells (Cell Probe, NA) | PBMC S-induced activation marker- positive T-cells (AIM, NA) | Fair |
| Bigaut et al. (France) ¹⁵ | 28 (28, 0) | BNT162b2 (mRNA) mRNA-1273 (mRNA) | Serum anti-RBD IgG (CMIA, Abbot; ECLIA, Roche) | NA | Fair |
| Brill et al. (Israel) ⁴⁷ | 112 (72, 40) | BNT162b2 (mRNA) | Serum anti-S IgG (CLIA, DiaSorin) Serum anti-RBD IgG (CMIA, Abbot) | PBMC S/N-induced IFN-g-positive T- cells (ELISpot, Oxford Immunotec) | Fair |
| Capone et al. (Italy) ¹⁶ | 140 (140, 0) | BNT162b2 (mRNA) | Serum anti-RBD IgG (CMIA, Abbot) | NA | Good |
| Capuano et al. (Italy) 36 | 57 (26, 31) | BNT162b2 (mRNA) | Serum anti-S IgG (CLIA, DiaSorin) | NA | Good |
| Disanto et al. (Switzerland) ²⁷ | 116 (116, 0) | BNT162b2 (mRNA) mRNA-1273 (mRNA) | Serum anti-RBD IgG (CMIA, Abbot) | NA | Good |
| Etemadifar et al. (Iran) | 358 (144, 214) | BBIBP-CorV (Inactivated) | Serum anti-S IgG (ELISA, Pishtazteb) | NA | Good |
| Gadani et al. (USA) ¹⁷ | 101 (101, 0) | BNT162b2 (mRNA) mRNA-1273 (mRNA) Ad26.COV2.S (AV) | Serum anti-S1 lgG (ELISA, EUROIMMUN) | PBMC S-induced IFN-g-positive T- cells (FluoroSpot, Mabtech) | Fair |
| Gallo et al. (Italy) ⁸² | 59 (4, 55) | BNT162b2 (mRNA) | Serum anti-S IgG (CLIA, DiaSorin) | NA | Fair |
| Giossi et al. (Italy) 18 | 312 (39, 273) | BNT162b2 (mRNA) | Serum anti-RBD IgG (CMIA, Abbot) | NA | Fair |
| Katz et al. (USA) ⁴⁹ | 48 (48, 0) | BNT162b2 (mRNA) mRNA-1273 (mRNA) Ad26.COV2.S (AV) | Serum anti-RBD IgG (ECLIA, Roche) | Rearranged TCR gene sequences (M-PCR, Adaptive Biotechnologies) | Fair |
| Ko⊡nig et al. (Norway) ₃₀ | 1155 (528, 627) | BNT162b2 (mRNA) mRNA-1273 (mRNA) ChAdOx1 (AV) | PBMC S-induced IgG-secreting B-cells (BBFCA, NA) PBMC RBD-induced IgG- secreting B-cells (BBFCA, NA) | NA | Fair |
| Madelon et al. (Switzerland) ⁴⁶ | 48 (26, 22) | BNT162b2 (mRNA) mRNA-1273 (mRNA) | Serum anti-RBD IgG (ECLIA, Roche) | PBMC S-induced activation marker- positive T-cells (AIM, NA) | Fair |
| Maniscalco et al. (Italy) | 149 (125, 24) | BNT162b2 (mRNA) | Serum anti-RBD IgG (ECLIA, Roche) | NA | Good |
| Ozakbas et al. | 591 (547, 44) | BNT162b2 (mRNA) | Serum anti-RBD IgG (CMIA, | NA | Good |

| (Turkey) ²² | | CoronaVac | Abbot) | | | |
|-----------------------------|---------------|------------------|--------------------------------------|--------------------------------------|------|--|
| | | (Inactivated) | | | | |
| Pitzalis et al. (Italy) 28 | 975 (912, 63) | BNT162b2 (mRNA) | Serum anti-RBD IgG (ECLIA, Roche) | NA | Fair | |
| Pompsch et al. | 30 (10, 20) | BNT162b2 (mRNA) | Serum anti-S1 IgG (ELISA, | S/N/M-induced IFN-g-positive T-cells | Fair | |
| (Germany) 48 | | | EUROIMMUN) | (ELISpot, Miltenyi Biotec) | | |
| Sabatino et al. (USA) | 80 (67, 13) | BNT162b2 (mRNA) | PBMC S-induced IgG-secreting | PBMC S-induced activated T-cells | Fair | |
| 23 | | mRNA-1273 | B-cells (BBFCA, NA) | (AIM; ICS; pMHC, NA) | | |
| | | (mRNA) | PBMC RBD-induced IgG- | | | |
| | | Ad26.COV2.S (AV) | secreting B-cells (BBFCA, NA) | | | |
| Sormani et al. (Italy) | 780 (780, 0) | BNT162b2 (mRNA) | Serum anti-RBD IgG (ECLIA, | NA | Good | |
| 25,62 | | mRNA-1273 | Roche) | | | |
| | | (mRNA) | | | | |
| Tallantyre et al. (UK) 29 | 473 (473, 0) | BNT162b2 (mRNA) | Serum anti-RBD IgG (ELISA, | PBMC S/N/M-induced IFN-g-positive | Fair | |
| | | ChAdOx1 (AV) | Kantaro Biosciences; GloBody, | T-cells (ELISpot, ImmunoServ Ltd.) | | |
| | | Ad26.COV2.S (AV) | NA) | | | |
| Tortorella et al. (Italy) | 186 (108, 78) | BNT162b2 (mRNA) | Serum anti-RBD IgG (NR) | Whole blood S-induced IFN-g | Fair | |
| 20 | | mRNA-1273 | Neutralizing antibodies (MNA, | (ELISA, ProteinSimple) | | |
| | | (mRNA) | NA) | | | |
| Tu⊡rkog⊡lu et al. | 59 (34, 25) | CoronaVac | Serum anti-S1 IgG (ELISA, | NA | Fair | |
| (Turkey) 31 | | (Inactivated) | EUROIMMUN) | | | |
| Van Kempen et al. | 87 (87, 0) | mRNA-1273 | Serum anti-RBD IgG (ELISA, NR) | NA | Fair | |
| (Netherlands) 83 | | (mRNA) | | | | |
| | | | | | | |
| Studies with no | | | - | | | |
| comparators | | | | | | |
| Guerrieri et al. (Italy) 84 | 32 (32, 0) | BNT162b2 (mRNA) | Various assays | NA | NA | |
| | | mRNA-1273 | | | | |
| | | (mRNA) | | | | |
| Novak et al. (Denmark, | 60 (60, 0) | mRNA vaccines | Serum anti-RBD IgG (CMIA, | NA | NA | |
| USA) ⁸⁵ | | | Abbot) | | | |
| Grothe et al. | 38 (38, 0) | BNT162b2 (mRNA) | Serum anti-S IgG (CLIA, | NA | NA | |
| (Germany) ⁴¹ | | mRNA-1273 | DiaSorin) | | | |
| | | (mRNA) | | | | |
| | | ChAdOx1 (AV) | | | | |

*Assessed with National Institutes of Health quality assessment tools (The rationale of judgements are presented in an online supplementary file; The used criteria are available at: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools). Good means least risk of bias; Fair, low risk of bias; and Poor, moderate/high risk of bias.

**Including two participants with neuromyelitis optica and two with optic neuritis.

Abbreviations: pwMS, people with multiple sclerosis; HC, healthy controls; mRNA, messenger ribonucleic acid; S, spike protein; PBMC, peripheral blood mononuclear cells; IFN-g, interferon-gamma; IL, interleukin; RBD, receptor-binding domain; CLIA, chemiluminescent immunoassay; NA, not applicable; AIM, activation-induced marker; CMIA, chemiluminescence microparticle immunoassay; ECLIA, electrochemiluminescence immunoassay; AV, adenoviral vector; N, nucleocapsid protein; M-PCR, multiplex polymerase chain reaction; BBFCA, bead-based flowcytometry assay; M, membrane protein; NR, not reported; ICS, Intracellular cytokine staining; pMHC, peptide major histocompatibility complex; MNA, microneutralization assay;

606

607 Table 2; Summary of Findings. Results with statistically-significant P-values are bolded.

| Factors (ref) | Post-vac outcomes | | | | | | | | |
|-----------------------|-------------------|-------------------------|-----------------|-----------------------------|--------------|---------------------------|---------------|-----------------------------|--|
| | B-cell response | | T-cell response | | | | | | |
| | Seroconversion | | IFN-g release | | CD4+ AIM+ | | CD8+ AIM+ | | |
| | OR | P-value | OR | P-value | OR | P-value | OR | P-value | |
| | (95% CI) | (certainty*) | (95% CI) | (certainty*) | (95% CI) | (certainty*) | (95% CI) | (certainty*) | |
| DMT (UX) | | | | | | | | | |
| -IFN | 0.84 | 0.66 | 0.02 <0.01 | | Ni | | Ni | | |
| | (0.38, 1.83) | Moderate ^{1,2} | (0.00, 0.14) | Very Low ^{2,4,5} | | | | | |
| -GA | 0.87 | 0.79 | Ni | | NE | | 0.62 | 0.72 | |
| | (0.31, 2.42) | Moderate ^{1,2} | | | | | (0.04, 9.00) | Very Low ^{1,2,4,5} | |
| -DMF | 1.98 | 0.07 | Ni | | NE | | 3.78 | 0.39 | |
| | (0.96, 4.09) | Moderate ^{1,2} | | | | | (0.18, 78,38) | Very Low ^{1,2,4,5} | |
| -TERI | 0.38 | 0.03 | Ni | | Ni | | Ni | | |
| | (0.16, 0.90) | Very Low ^{2,3} | | | | | | | |
| -S1PRM | 0.04 | <0.00001 | 0.04 | <0.00001 | 0.01 | 0.001 | 0.95 | 0.97 | |
| | (0.03, 0.06) | High ¹ | (0.02, 0.07) | Low ^{1,2,3} | (0.00, 0.18) | Very Low ^{2,4,5} | (0.08, 10.71) | Very Low ^{1,2,4,5} | |
| -NTZ | 0.53 | 0.12 | 1.00 | 1.00 | NE | | 3.95 | 0.35 | |
| | (0.24, 1.18) | Low ^{1,2,4} | (0.20, 5.12) | Very Low ^{1,2,4,5} | | | (0.23, 69.44) | Very Low ^{1,2,4,5} | |
| -CLAD | 0.41 | 0.08 | 0.01 | <0.00001 | Ni Ni | | 1 | | |
| | (0.15, 1.11) | Low ^{1,2,5} | (0.00, 0.04) | Low ^{1,2,5} | | | | | |
| -ALEM | 0.32 | 0.04 | Ni | | Ni | | Ni | | |
| | (0.10, 0.96) | Very Low ^{2,3} | | | | | | | |
| -aCD20 | 0.05 | <0.00001 | 1.12 | 0.70 | 1.13 | 0.90 | 2.54 | 0.08 | |
| | (0.04, 0.06) | High ¹ | (0.62, 2.05) | Moderate ^{1,3} | (0.17, 7.61) | Moderate ^{1,2} | (0.89, 7.27) | Moderate ^{1,5} | |
| aCD20 infusion-to-vac | 1.94 | <0.00001 | Ni | | Ni | | Ni | | |
| (per 10 weeks) | (1.57, 2.41) | High ¹ | | | | | | | |

*Based on GRADE approach (Baseline: moderate due to observational nature of studies; ▲upgrade; ▼downgrade):

1. ▲ Result in line with quantitative analyses in individual studies; 2. ▼ Low count of studies with measurable relative effect; 3. ▼ Inconsistency; 4. ▼ Risk of missing results; and 5. ▼ Imprecision.

Abbreviations: ref, reference; vac, vaccination; IFN-g, interferon-gamma; AIM, activation-induced marker; OR, odds ratio; CI, confidence interval; DMT, disease-modifying therapy; UX, unexposed; IFN, interferons; Ni, no information; GA, glatiramer acetate; NE, not estimable; TERI, teriflunomide; S1PRM, sphingosine-1-phosphate receptor modulators; NTZ, natalizumab; CLAD, cladribine; ALEM, alemtuzumab; aCD20, anti-CD20 therapies.

608

609 Figure Legends

- 610 Fig.1; PRISMA Flow Diagram. Abbreviation: pwMS, people with multiple sclerosis.
- 611 Fig.2; Summary forest plot of the pooled results. Abbreviations: UX, unexposed; ref, reference; DMF,
- 612 dimethyl fumarate; GA, glatiramer acetate; IFN, interferons; NTZ, natalizumab; CLAD, cladribine; TERI,
- 613 teriflunomide; ALEM, alemtuzumab; aCD20, anti-CD20; S1PR, sphingosine-1-phosphate receptor
 - 614 modulators; IFN-g, interferon-gamma; AIM, activation-induced marker.
 - 615 Fig.3; Schematic curve showing the association of post-vaccination seroconversion rates with time since
 - 616 last anti-CD20 infusion. *Current guideline recommendations on minimum delay of vaccination after anti-
 - 617 CD20 infusion. Abbreviations: UX, unexposed; aCD20, anti-CD20.

Identification of studies via databases and registers















